Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1
Abstract
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (11)
Joshua E. Reuss
Georgetown University, Washington, DC
Sara Kuruvilla
London Health Sciences Centre, London, ON, Canada
Nofisat Ismaila
American Society of Clinical Oncology (ASCO), Alexandria, VA, US
Ibrahim Hanna Azar
IHA Hematology Oncology Consultants, Ypsilanti, MI
Jill Feldman
Patient Advocate EGFR Resisters Deerfield Illinois USA
Naoki Furuya
St Marianna University School of Medicine, Kawasaki, Japan
Paul Wheatley-Price
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
Logan Roof
Ohio State University, Columbus, OH
Ana I. Velazquez
Yubao Wang
Department of Cancer Biology, Dana-Farber Cancer Institute
Natasha B. Leighl